We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension (Epitome2ext)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01470144
Recruitment Status : Completed
First Posted : November 11, 2011
Results First Posted : December 9, 2016
Last Update Posted : June 26, 2017
Chiltern International Ltd.
Information provided by (Responsible Party):

Brief Summary:
This is an open-label, nonrandomized extension to study AC-066A301. The study will assess safety and tolerability of ACT-385781A while providing a means for continuing treatment after ending participation in study AC-066A301.

Condition or disease Intervention/treatment Phase
Pulmonary Arterial Hypertension Drug: Epoprostenol Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Extension of Study AC-066A301 Investigating the Safety and Tolerability of ACT-385781A in Patients With Pulmonary Arterial Hypertension (PAH)
Actual Study Start Date : June 1, 2011
Primary Completion Date : June 1, 2015
Study Completion Date : July 1, 2015

Arm Intervention/treatment
Experimental: Treatment
Single arm, open-label
Drug: Epoprostenol
Administered by continuous intravenous infusion via a central venous catheter; using an ambulatory infusion pump. The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit

Primary Outcome Measures :
  1. Treatment-emergent Adverse Events [ Time Frame: On average 2.72 years ]

Secondary Outcome Measures :
  1. Exposure Duration [ Time Frame: On average 2.72 years ]
    Duration of exposure to EFI

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Signed informed consent prior to initiation of any study-mandated procedure
  2. Patients who completed participation in study AC-066A301
  3. Patients who have not obtained access for commercial EFI at the time of ending participation in study AC-066A301

Exclusion Criteria:

  1. Patients who prematurely discontinued study drug in study AC-066A301
  2. Patients for whom continued treatment with EFI is no longer considered appropriate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01470144

UZ Gasthuisberg
Leuven, Belgium, 3000
Canada, Ontario
University of Toronto
Toronoto, Ontario, Canada, M5G 2N2
Canada, Quebec
Sir Mortimer B Davis Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
CHU Caen
Caen, France
Hôpital Kremlin Bicêtre
Paris, France
Ospedale Sant'Orsola
Bologna, Italy, 40438
Amsterdam, Netherlands
Hospital 12 de Octubre
Madrid, Spain
Sponsors and Collaborators
Chiltern International Ltd.

Responsible Party: Actelion
ClinicalTrials.gov Identifier: NCT01470144     History of Changes
Other Study ID Numbers: AC-066A302
First Posted: November 11, 2011    Key Record Dates
Results First Posted: December 9, 2016
Last Update Posted: June 26, 2017
Last Verified: June 2017

Additional relevant MeSH terms:
Familial Primary Pulmonary Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases